BioLamina published an application note titled Modelling the kidney in 2D and 3D exploring how full-length Biolaminin 521 and 511 support kidney research.
Public source
Publisher name
Public post
Kidney Awareness Week is an important opportunity to highlight how the right cellular microenvironment can support more physiologically relevant kidney models. Our kidne…
Company
BioLamina
Cell-specific culture matrices for improved cell functionality
- Industry
- Biotechnology Research
- Location
- Sundbyberg, SE
- Company size
- 51–200 employees
About BioLamina
BioLamina is a biotechnology company with a scientific base and heritage in matrix biology and cell culture research. It supports scientists who have struggled for decades to grow pluripotent stem cells and other primary cells in the lab. By providing tools for efficient and easy cell culture, BioLamina aims to ease the path towards safe and effective cell therapies and make better cell assays and models for increasing accuracy in drug discovery and development. The power of Biolaminin® substrates, developed by BioLamina, has been demonstrated in numerous publications, and they will continue to provide vital support to the stem cell community, from scientific concepts to clinical studies.
See moreLatest activity
Latest activity from BioLamina
3 signals
Presence & Recognition
BioLamina colleague Elias Uhlin will attend the German Stem Cell Network (GSCN) Conference 2026 in Berlin representing the company.
Research & Knowledge
BioLamina published a study by Meyer et al. (2026) in which researchers cultured human renal proximal tubular epithelial cells on Biosilk 521—a recombinant spider silk membrane coated with Biolaminin 521 to mimic the kidney basement membrane.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
MatTek Life Sciences
MatTek Life Sciences published a case study detailing the EpiVaginal 3D human vaginal tissue model for evaluating vaginal products and their safety strategies.
Research & Knowledge
PeptiMatrix
PeptiMatrix features as part of the work in the new National Centre for the Replacement, Refinement and Reduction of Animals in Research Impact Report, highlighting its collaboration with Dr Mattéa Finelli at the University of Nottingham, STRATASTEM LIMITED, and Dr Richard Elsworthy at the University of Birmingham.
Research & Knowledge
Advanced In Vitro, LLC
Advanced In Vitro, LLC reports that the native architecture, complement of cell types, and inherent primary tissue properties include airway contractility and stiffness, both useful for therapeutic efficacy studies.
Research & Knowledge
Celvivo
Celvivo published a study in Cell Reports by Cell Press published in 2026 detailing the development of rotational 3D trophoblast organoids in Tohoku University School of Medicine, ROHTO Pharmaceutical Co., Ltd., and the Institute of Molecular Embryology and Genetics at Kumamoto University.
Research & Knowledge
Qkine